Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $12.8 million.

  • Applied Therapeutics' Change in Accured Expenses rose 30159.72% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 38553.4%. This contributed to the annual value of $1.2 million for FY2024, which is 6000.0% up from last year.
  • According to the latest figures from Q3 2025, Applied Therapeutics' Change in Accured Expenses is $12.8 million, which was up 30159.72% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Applied Therapeutics' Change in Accured Expenses ranged from a high of $12.8 million in Q3 2025 and a low of -$6.7 million during Q1 2025
  • For the 3-year period, Applied Therapeutics' Change in Accured Expenses averaged around $840545.5, with its median value being $319000.0 (2023).
  • In the last 5 years, Applied Therapeutics' Change in Accured Expenses tumbled by 132884.01% in 2024 and then skyrocketed by 30159.72% in 2025.
  • Over the past 3 years, Applied Therapeutics' Change in Accured Expenses (Quarter) stood at $3.5 million in 2023, then fell by 25.16% to $2.7 million in 2024, then skyrocketed by 383.16% to $12.8 million in 2025.
  • Its Change in Accured Expenses stands at $12.8 million for Q3 2025, versus $1.2 million for Q2 2025 and -$6.7 million for Q1 2025.